sub:assertion {
  d:DB01072 v:identifier "DB01072" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB01072" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB01072> ;
    dv:drugbank-id "APRD00804" , "DB01072" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:08:18.08.08> ;
    dv:x-atc <http://bio2rdf.org/atc:J05AE08> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:13934> ;
    dv:x-cas <http://bio2rdf.org/cas:198904-31-3> ;
    dv:x-chebi <http://bio2rdf.org/chebi:37924> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:130642> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2248610> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01276> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA10251> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:148192> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46508504> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Atazanavir> ;
    dct:description "Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]"@en ;
    dct:identifier "drugbank:DB01072" ;
    dct:title "Atazanavir"@en ;
    a dv:Drug ;
    rdfs:label "Atazanavir [drugbank:DB01072]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB01072> , <http://www.drugs.com/cdi/atazanavir.html> , <http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rey1671.shtml> , <http://www.rxlist.com/cgi/generic/reyataz.htm> .
}